Oak Hill Bio Ltd.
- Biotech or pharma, therapeutic R&D
Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics that have been deprioritized from big pharma. The company’s pipeline includes programs in late-stage clinical development: OHB-724 (rugonersen), a potentially best-in-class Phase 3-ready antisense oligonucleotide (ASO) treatment for Angelman syndrome (a severe neurodevelopmental disorder), and OHB-607, recombinant human IGF-1/IGFBP-3 for complications of extremely premature birth, currently in a Phase 2b trial.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}